Skip to main content
Caplight Logo









bioGenous Biotechnology

bioGenous Biotechnology

Private
SuzhouHealthcare & Life Scienceshttp://biogenous.cn/

Last Round

Series A

Extension

Dec 31, 2024

Total Funding Raised

$14.7M

Company Overview

bioGenous Biotechnology is a biotechnology company that specializes in organoid construction, drug testing, and multi-omics analysis, providing standardized organoid products and integrated technical services for the biopharmaceutical industry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Biotech Equipment, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Data as a Service

AI Layer

Application

Keywords

organoid technologyCRDMOorganoid culturedrug discoveryprecision medicinepatient-derived organoidsorgan-on-a-chipmulti-omics analysisNGS sequencingbiotech lab automation3D cell culturedrug screeningtranslational researchlab-grown tissuebiotech reagents

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

bioGenous Biotechnology Comparables

Compare bioGenous Biotechnology with similar companies based on industry and business-model similarity.

bioGenous Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
K2 Oncology
87%
AimingMed
87%
Accurate International Biotechnology
84%

bioGenous Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 31, 2024
Series AJan 5, 2023
Early FundingOct 14, 2022
AngelAug 10, 2021

bioGenous Biotechnology Investors

Notable investors and investment history

bioGenous Biotechnology investors
InvestorRounds
SDIC Fund ManagementSeries A
Marathon Venture PartnersSeries A, Early Funding
源创多盈投资Early Funding, Angel
CICC CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 31, 2024

    Led by CICC Capital

  • Jan 5, 2023

    $15M round led by SDIC Fund Management.

bioGenous Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

bioGenous Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about bioGenous Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range4
Year Founded2021
Last FundingDec 31, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?